Thyroid Nodule Drugs: Medications That Cause or Treat Thyroid Nodules

Why Some Drugs Cause Thyroid Nodules

Certain medications alter thyroid hormone synthesis, iodine metabolism, or glandular blood flow in ways that promote nodular growth. The thyroid gland is uniquely sensitive to disruptions in the hypothalamic-pituitary-thyroid axis, and chronic pharmacologic interference can trigger compensatory hyperplasia that develops into discrete nodules over months or years.

Lithium

Lithium carbonate, prescribed to roughly 1.5 million Americans for bipolar disorder, concentrates in the thyroid at levels 3 to 4 times higher than serum [1]. It inhibits thyroid hormone release, blocks iodine organification, and reduces T4-to-T3 conversion. A prospective study of 100 lithium-treated patients found that 50% developed goiter and 27% developed new thyroid nodules after a mean exposure of 4.5 years [2]. The ATA recommends thyroid ultrasound and TSH monitoring every 6 to 12 months for patients on chronic lithium therapy [3].

Amiodarone

Amiodarone contains 37% iodine by weight. A single 200 mg daily dose delivers approximately 7 mg of free iodine, roughly 50 times the recommended daily intake [4]. This iodine load can trigger either amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH), both of which promote nodular change. Studies report new thyroid nodule formation in 15 to 20% of patients within the first two years of amiodarone use [5]. Monitoring includes thyroid function tests every 3 months and baseline ultrasound before starting the drug.

Interferon-Alpha and Tyrosine Kinase Inhibitors

Interferon-alpha, once a standard therapy for hepatitis C, induced thyroid dysfunction in 5 to 15% of treated patients, with nodule formation reported in long-term cohorts [6]. Tyrosine kinase inhibitors (TKIs) such as sunitinib and imatinib impair thyroid hormone synthesis through multiple mechanisms, including reduced thyroidal blood flow, accelerated T4 clearance, and direct glandular toxicity. In a retrospective analysis of 96 patients receiving sunitinib for renal cell carcinoma, hypothyroidism developed in 53%, and thyroid nodules were noted in 14% during follow-up imaging [7].

Drugs Used to Treat Benign Thyroid Nodules

The majority of thyroid nodules are benign. Treatment decisions hinge on nodule size, growth rate, functional status, and patient symptoms. The ATA 2015 guidelines recommend against routine pharmacologic treatment of most benign nodules, favoring active surveillance with serial ultrasound [3].

Levothyroxine Suppression Therapy

Levothyroxine (T4) suppression therapy aims to reduce TSH below 0.1 mIU/L, removing the growth stimulus for TSH-dependent nodular tissue. This approach was widely used through the 1990s but has fallen out of favor for most patients. A Cochrane review of 6 randomized controlled trials (N=346) found that levothyroxine suppression reduced nodule volume by 0.4 to 0.6 mL compared to placebo, a clinically modest effect [8]. The ATA 2015 guidelines recommend against routine TSH suppression for benign nodules in iodine-sufficient populations due to risks of atrial fibrillation (OR 3.1 in adults over 60) and accelerated bone loss in postmenopausal women [3].

Specific clinical scenarios where suppression may still be considered include young patients with small nodules in documented iodine-deficient regions. The target TSH in these cases is 0.4 to 1.0 mIU/L, not full suppression.

Observation Alone

For nodules classified as Bethesda II (benign) on fine-needle aspiration, the ATA recommends repeat ultrasound at 12 to 24 months. If no significant growth occurs (defined as a 20% increase in at least two dimensions with a minimum increase of 2 mm, or a 50% or greater increase in volume), the interval can extend to every 3 to 5 years [3].

Treating Hyperfunctioning (Toxic) Thyroid Nodules

Autonomously functioning thyroid nodules, sometimes called "hot" nodules on radioiodine scan, produce excess thyroid hormone independent of TSH stimulation. These account for roughly 5 to 10% of all thyroid nodules and are almost never malignant.

Radioactive Iodine (I-131)

Radioactive iodine-131 is considered first-line definitive therapy for toxic adenomas and toxic multinodular goiter in North America [3]. A single dose of 10 to 30 mCi resolves hyperthyroidism in 75 to 100% of cases within 6 to 18 months. A meta-analysis of 28 studies (N=1,550) showed a cure rate of 89% with a single dose [9]. The primary risk is post-treatment hypothyroidism, occurring in 10 to 20% of patients with solitary toxic adenomas and 40 to 60% of those with multinodular goiter, requiring lifelong levothyroxine replacement.

Methimazole

Methimazole is the preferred antithyroid drug in the United States for managing hyperthyroidism from toxic nodules. It blocks thyroid peroxidase, inhibiting iodine organification and the coupling of iodotyrosines. Starting doses of 5 to 20 mg daily normalize thyroid function in 4 to 8 weeks for most patients [10]. Methimazole serves two roles: as definitive long-term therapy for patients who decline surgery or radioactive iodine, and as a bridge to normalize thyroid hormone levels before definitive treatment.

Side effects include rash (5%), arthralgia (1 to 2%), and the rare but serious agranulocytosis (0.2 to 0.5%), which mandates immediate white blood cell monitoring if fever or sore throat develops. Propylthiouracil (PTU) is an alternative reserved for the first trimester of pregnancy and patients with methimazole allergy.

Beta-Blockers as Symptomatic Control

Propranolol 20 to 40 mg three times daily or atenolol 25 to 50 mg daily controls adrenergic symptoms (tremor, tachycardia, anxiety) while methimazole takes effect. Beta-blockers do not alter thyroid hormone levels. They are a bridge, not a treatment.

Pharmacotherapy for Malignant Thyroid Nodules

When fine-needle aspiration or surgical pathology confirms thyroid cancer, the treatment approach shifts to TSH suppression (for differentiated types) and targeted systemic therapy (for advanced or radioiodine-refractory disease).

Levothyroxine TSH Suppression After Thyroidectomy

For differentiated thyroid cancers (papillary and follicular subtypes, which account for over 90% of thyroid malignancies), levothyroxine is prescribed post-thyroidectomy at doses sufficient to suppress TSH. The 2015 ATA guidelines stratify the suppression target by risk [3]:

• High-risk (distant metastases, gross extrathyroidal extension): TSH <0.1 mIU/L
• Intermediate-risk: TSH 0.1 to 0.5 mIU/L
• Low-risk (intrathyroidal, N0, M0): TSH 0.5 to 2.0 mIU/L (near-normal range)

"Excessive TSH suppression in low-risk patients exposes them to cardiovascular and skeletal harm with no proven oncologic benefit," the 2015 ATA guideline panel wrote [3]. This risk-adapted approach replaced the prior one-size-fits-all suppression philosophy.

Lenvatinib (Lenvima)

Lenvatinib is a multi-target TKI that inhibits VEGFR1-3, FGFR1-4, PDGFR-alpha, RET, and KIT. The SELECT trial (N=392) randomized patients with radioiodine-refractory differentiated thyroid cancer to lenvatinib 24 mg daily or placebo [11]. Median progression-free survival was 18.3 months with lenvatinib versus 3.6 months with placebo (HR 0.21; 99% CI, 0.14 to 0.31; P<0.001). The objective response rate was 64.8%, including four complete responses. The FDA approved lenvatinib for this indication in February 2015.

Common adverse events include hypertension (67.8%), diarrhea (59.4%), fatigue (59.0%), and decreased appetite (50.2%). Dose reductions were required in 67.8% of patients, and 14.2% discontinued due to adverse events [11].

Sorafenib (Nexavar)

Sorafenib was the first TKI approved for radioiodine-refractory differentiated thyroid cancer, based on the DECISION trial (N=417) [12]. Patients randomized to sorafenib 400 mg twice daily had a median progression-free survival of 10.8 months versus 5.8 months with placebo (HR 0.59; 95% CI, 0.45 to 0.76; P<0.001). The partial response rate was 12.2%. Hand-foot skin reaction (76.3%), diarrhea (68.6%), and alopecia (67.1%) were the most frequent adverse events.

Newer Targeted Agents: RET and BRAF Inhibitors

Two precision-oncology agents have expanded the thyroid cancer pharmacopeia since 2020:

Selpercatinib (Retevmo): FDA-approved in 2020 for RET-fusion-positive thyroid cancers and RET-mutant medullary thyroid carcinoma. The LIBRETTO-001 trial showed a 79% objective response rate in RET-fusion DTC patients (N=19) [13].

Dabrafenib plus trametinib: FDA-approved in 2022 for BRAF V600E-mutant anaplastic thyroid cancer, based on a cohort of 36 patients showing a 56% overall response rate in one of the deadliest malignancies known (median overall survival for anaplastic thyroid cancer is historically 3 to 5 months) [14].

Drugs That Shrink Benign Nodules: What the Evidence Shows

Beyond levothyroxine suppression, researchers have tested several agents for benign nodule reduction. Results have been inconsistent.

Percutaneous Ethanol Injection (PEI)

Though technically a procedure rather than a systemic drug, PEI deserves mention. It involves injecting 95% ethanol directly into cystic or predominantly cystic nodules under ultrasound guidance. A randomized trial of 66 patients with recurrent cystic nodules showed a 79% volume reduction at 12 months with PEI versus 47% with simple aspiration [15]. The 2015 ATA guidelines support PEI for recurrent, symptomatic cystic nodules that are not surgical candidates [3].

Iodine Supplementation in Deficient Populations

In regions with documented iodine deficiency (parts of Europe, Central Asia, sub-Saharan Africa), iodine supplementation reduces the incidence of new nodule formation. A Swiss population study showed a 50% reduction in multinodular goiter prevalence over 20 years following salt iodization [16]. This is prevention rather than treatment, but it remains the single most effective public health intervention against nodular thyroid disease globally.

When to Switch from Monitoring to Medication

Not every thyroid nodule warrants a prescription. The decision tree depends on four variables: cytology result, functional status, size trajectory, and symptom burden.

Indications for Pharmacologic Intervention

A benign nodule that remains stable on two consecutive ultrasounds (typically over 3 to 5 years) needs no medication. Medication enters the picture when:

• The nodule is autonomously functioning and producing clinical or subclinical hyperthyroidism (methimazole or radioactive iodine)
• FNA returns Bethesda V or VI (suspicious or malignant), leading to surgery followed by levothyroxine and possibly targeted therapy
• The patient has compressive symptoms from a large multinodular goiter and declines or is unfit for surgery (radioactive iodine may reduce goiter volume by 40 to 60% over 1 to 2 years) [9]

Medication Review for Nodule Prevention

Patients on lithium, amiodarone, or long-term TKI therapy should undergo thyroid ultrasound at baseline and annually. If new nodules appear, the risk-benefit calculation of continuing the causative drug should involve both the prescribing specialist and an endocrinologist. Stopping lithium solely because of a thyroid nodule is rarely justified; managing the thyroid consequences while continuing psychiatric treatment is the standard approach.

"For patients on amiodarone, thyroid function should be assessed before initiation and every 3 to 6 months during treatment," according to the 2021 European Thyroid Association guidelines on amiodarone-associated thyroid dysfunction [5].

Diagnostic Workup Before Starting Any Thyroid Nodule Drug

No medication should be started without a complete diagnostic evaluation. Prescribing levothyroxine for an uncharacterized nodule, for example, could mask or worsen an autonomous nodule causing subclinical hyperthyroidism.

The Standard Workup

1. TSH level. A low TSH suggests a hyperfunctioning nodule; a normal or elevated TSH prompts FNA based on ultrasound features.
2. Thyroid ultrasound. The TI-RADS scoring system (ACR, 2017) standardizes which nodules need FNA based on composition, echogenicity, shape, margin, and echogenic foci [17].
3. Fine-needle aspiration (FNA). Guided by TI-RADS category. The Bethesda System for Reporting Thyroid Cytopathology classifies results into six categories, each with an associated malignancy risk (ranging from 1 to 4% for Bethesda II to 97 to 99% for Bethesda VI) [18].
4. Molecular testing. For Bethesda III/IV (indeterminate) nodules, gene expression classifiers (Afirma GSC) or next-generation sequencing panels (ThyroSeq v3) can refine malignancy risk and guide the decision between observation and surgery.

When Imaging Changes the Drug Plan

A nodule initially thought benign may show interval growth or develop suspicious features on follow-up ultrasound (new microcalcifications, taller-than-wide shape, irregular margins). In these cases, repeat FNA takes priority over any medication adjustment. The 2015 ATA guidelines define clinically significant growth as a 20% increase in at least two dimensions with a minimum 2 mm increase in each [3].